NFKB1 and pulmonary fibrosis: In addition, when DMY was used to interfere with fibrotic lung injury induced by methotrexate, it was found through lung histopathological examination that DMY could reduce the levels of NF-κB, IL-1β and TGF-β1 to inhibit lung inflammation and pulmonary fibrosis [19].